Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head AnalysisDefense World · Oct 9, 2026
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®GlobeNewsWire · Sep 22, 2026
Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without ModificationGlobeNewsWire · Sep 14, 2026
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 2, 2026
MediWound Ltd. (MDWD) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
MediWound Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.76 | -$0.77 | Miss |
| May 27, 2026 | -$0.65 | -$0.23 | Beat |
| Mar 5, 2026 | -$0.65 | -$0.56 | Beat |
| Nov 20, 2025 | -$0.81 | -$0.24 | Beat |
| Aug 14, 2025 | -$0.55 | -$1.23 | Miss |
| May 21, 2025 | -$0.65 | -$0.07 | Beat |